OTC · DSNKY
Healthcare · Drug Manufacturers - General
$17.14
Down-$0.36 (-2.06%)
Updated Aug 14, 2026, 7:20 PM
SID Score
4.6/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
DSNKY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning DSNKY.
DSNKY research
Company profile and research snapshot.
DAIICHI SANKYO S/ADR
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Feb 19, 2026
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1If approved, Daiichi Sankyo and AstraZeneca's ENHERTU has the
SeekingAlpha · Feb 2, 2026
Daiichi Sankyo (DSNKY) Q3 FY2025 earnings: ENHERTU and DATROWAY sales surge
Benzinga · Jan 30, 2026
Daiichi Sankyo Co (OTC:DSNKY) reported quarterly earnings of $0.30 per share. This is unchanged from the same period last year. The company reported $3.623 billion in sales this quarter. This is a 6.53 percent increase
SeekingAlpha · Jan 30, 2026
Daiichi Sankyo Company, Limited (DSNKY) Q3 2026 Earnings Call January 30, 2026 1:00 AM ESTCompany ParticipantsKentaro Asakura - Corporate Officer, Head of...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DSNKY.
